

Nektar Therapeutics(NKTR)

\$23.76 (As of 06/22/20)

Price Target (6-12 Months): **\$25.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 01/01/20)

Prior Recommendation: Outperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM:F

Value: F

Growth: F

Momentum: B

Summary

Nektar beat Q1 earnings and revenue estimates. The company has a promising pipeline with several regulatory updates/data-readouts lined up for 2020. Moreover, regular partnerships have enhanced the company's financial position. The blockbuster collaboration deal with Bristol-Myers for NKTR-214 significantly boosted Nektar's cash resources. It also has encouraging co-development deals with other pharma companies. The deals boost revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company's results in the future. Shares of the company have underperformed the industry in the past year.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$36.85 - \$13.63
20 Day Average Volume (sh)	1,246,767
Market Cap	\$4.2 B
YTD Price Change	8.6%
Beta	1.98
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Drugs
Zacks Industry Rank	Top 29% (73 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	34.6%
Last Sales Surprise	12.5%
EPS F1 Est- 4 week change	0.0%
Expected Report Date	08/13/2020
Earnings ESP	0.0%
P/E TTM	NA
P/E F1	NA
PEG F1	NA
P/S TTM	30.5

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	31 E	26 E	25 E	26 E	144 E
2020	51 A	23 E	50 E	23 E	147 E
2019	28 A	23 A	29 A	34 A	115 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	-\$0.67 E	-\$0.73 E	-\$0.75 E	-\$0.78 E	-\$2.45 E
2020	-\$0.53 A	-\$0.69 E	-\$0.57 E	-\$0.77 E	-\$2.84 E
2019	-\$0.68 A	-\$0.63 A	-\$0.56 A	-\$0.64 A	-\$2.52 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 06/22/2020. The reports text is as of 06/23/2020.

Overview


San Francisco, CA-based Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms.

Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Bayer, Roche, Amgen, Bristol-Myers and Eli Lilly among others.

Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. AstraZeneca's opioid-induced constipation (OIC) drug, Movantik; Takeda's hemophilia A therapy, Adynovate; and Amgen's neutropenia drug, Neulasta are few of the drugs developed using Nektar's PEGylation platform.

Meanwhile, Nektar is developing several candidates targeting cancer and autoimmune therapeutic areas. Interesting ones include NKTR-358 (auto-immune and inflammatory diseases) and bempegaldesleukin (previously NKTR-214; several studies in cancer indications) among others.

Nektar generated total revenues of \$114.6 million in 2019 compared with \$1.19 billion in the year-ago period. The significant decrease was due to an upfront payment of \$1.06 billion received from Bristol-Myers related to a collaboration agreement in 2018.



Reasons To Buy:

- ▲ **Strong Pipeline Candidates Attracting Funds:** Nektar has deals with large pharma companies for developing its pipeline candidates. These deals provide the company with funds through upfront and milestone payments as well as enables sharing of research and marketing costs. These deals also bode well for Nektar as they provide the company strong expertise.

The company has a deal with Bristol-Myers to develop bempegaldesleukin (bempeg) in combination with Bristol-Myers' Opdivo or Yervoy. With this deal, Nektar received \$1 billion in upfront payments and is eligible to receive almost \$1.75 billion in future payments. Per the deal, Bristol-Myers also infused \$850 million in Nektar through the acquisition of the latter's common stock. The company is evaluating bempeg in combination with Bristol-Myers' Opdivo alone or with Yervoy under PIVOT program in more than 20 indications across nine tumor types, including melanoma, kidney, breast, bladder and non-small cell lung cancer.

It also has an oncology clinical collaboration with Takeda to develop bempeg in combination with the latter's TAK-659 in liquid and solid tumors. The company will develop doublet or triplet combination therapies of bempeg with Pfizer's Bavencio (avelumab), Talzenna (talazoparib) or Xtandi (enzalutamide) in several cancer indications, under a collaboration with Pfizer. Takeda and Pfizer share the costs related to clinical studies. Nektar is also developing a combination of bempeg and Merck's Keytruda as a treatment for non-small cell lung cancer.

Nektar has a co-development deal with Lilly to develop NKTR-358 in auto-immune and inflammatory diseases under which Lilly will bear the majority of development and commercialization costs. Nektar is also eligible to receive \$250 million in milestone payments and royalties. Under Nektar's research collaboration with Gilead, the clinical development costs for NKTR-255 in combination with the Gilead's antiretroviral therapies will be funded by Gilead.

- ▲ **Pipeline Progressing Well:** We are pleased with Nektar's efforts to build its internal pipeline. The company has a robust pipeline of early- and late-stage candidates. The company's primary immuno-oncology candidate, bempeg, is being evaluated as monotherapy or in combination with other drugs in several clinical studies, targeting multiple cancer indications. The company plans to file a regulatory application seeking approval for bempeg in one of the targeted indications, followed by launch, in 2021. Other pipeline candidates include NKTR-358 (systemic lupus erythematosus, psoriasis, atopic dermatitis; phase Ib), NKTR-255 (relapsed, refractory non-Hodgkin lymphoma or multiple myeloma; phase I) and NKTR-262 (in combination with bempegaldesleukin; refractory melanoma; phase II).

Successful development and commercialization of these candidates will likely boost the company's top line considering the lucrative markets they are targeting.

- ▲ **PEGylation Technology Generates Royalties:** Nektar's PEGylation technology has facilitated the development of more than ten approved products in the United States and the EU through partnerships with healthcare companies, including UCB's Cimzia and Amgen's Neulasta among others. These partnerships have significantly enhanced the company's financial position as it earns royalties on sales of partnered drugs.

Following deal generates major revenues for Nektar. The company has a collaboration agreement with Takeda for Adynovate for the treatment of hemophilia A. Nektar is entitled to receive royalties and sales milestones related to Adynovate. The company is entitled to significant and escalating double-digit royalty payments and sales milestone payments from AstraZeneca based on annual worldwide net sales of Movantik and Movantik fixed-dose combination products. Nektar also has license, manufacturing and supply agreements with several large pharmaceuticals, including Pfizer, related to approved drugs or drugs under development using PEGylation technology.

- ▲ **Favorable Debt Profile:** Nektar has a favorable debt profile. As of Mar31, 2020, the company's debt to total capital ratio stood at 0.24, which compared favorably with the industry's 0.52. A lower ratio indicates lower financial risk. Also, the company's total debt (current and long-term debt) was approximately \$412million as of March end. The company's cash, cash equivalents, and marketable securities totalling approximately \$1.35billion, at the end of March 2020, should be sufficient to pay the debt in case of insolvency.

The U.S. and EU approval of Movantik is a huge positive for Nektar. The company also boasts a robust pipeline. Moreover, its collaborations bode well for growth.

Reasons To Sell:

▼ **Overdependence on Partners:** Nektar relies heavily on partners for revenues in the form of collaboration, license and milestone payments. If the approved partnered drugs fail to achieve commercial success or if the candidates in development fail to generate positive late-stage outcomes sufficient to support regulatory approval in major markets, it could significantly impact the company's top line. For instance, following failure of IVERIC bio's late-stage candidate, Fovista, for the treatment of wet age-related macular degeneration, Nektar terminated its license and supply agreement with IVERIC bio in 2017. Therefore, the company's heavy dependence on its partners is concerning.

Nektar relies heavily on collaboration agreements for funds. Stiff competition remains a threat as well. Any hiccup on the development/regulatory front could adversely impact shares.

▼ **Pipeline and Regulatory Setbacks:** Gaining approval for pipeline candidates has become more difficult with an increasingly stringent regulatory environment. We note that Nektar is no stranger to pipeline setbacks. In January 2020, two FDA advisory committees did not recommend NKTR-181's approval. The company has withdrawn the NDA for the candidate and decided to stop further development of the candidate following the unfavorable decision. The company decided to terminate all development activities related to Onzeald in February 2020, following its failure in a late-stage breast cancer study.

In July 2019, Nektar informed that sub-optimal lots of bempegaldesleukin have led to reduced response rate in cancer patients evaluated in clinical studies under PIVOT program. Nektar is enrolling additional treatment-naïve NSCLC patients for consistent results, which will lead to delay in bempeg-Opdivo combo development.

The company has several pipeline-related updates upcoming over the next several quarters. Any additional hiccup on the development or regulatory front could pull down the stock significantly and hamper the company's growth prospects.

▼ **Stiff Competition:** Nektar's PEGylation and advanced polymer conjugate chemistry platforms and partnered and proprietary products in the market face competition from various pharmaceutical and biotechnology companies. Players in PEGylation and polymer conjugate chemistry technology space include Biogen, Dr. Reddy's, Horizon Pharma and Novo Nordisk, among others. Notably, Movantik faces competition from the currently available alternative therapies that are used to address OIC and opioid-induced bowel dysfunction (OBD), including Takeda's Amitiza, Bausch Health's Relistor, and oral and rectal over-the-counter laxatives and stool softeners. In addition, there are a number of companies, including Merck, Ironwood Pharmaceuticals, GlaxoSmithKline and others are developing treatments targeting OIC and OBD across different patient populations. Meanwhile, Adynovate faces competition from Biogen's Eloctate. In fact, competition is likely to increase with approvals of Bayer's Jivi and Novo Nordisk's Esperoct.

Upon approval, bempegaldesleukin will face stiff competition. The immuno-oncology segment is led by Merck's Keytruda, followed by Bristol-Myers' Opdivo and Roche's Tecentriq. Several candidates are also being developed by various pharma companies. Notably, NKTR-358 will compete with several drugs, which are approved or under development for autoimmune diseases, including Lilly's Olumiant and Galxo's Benlysta. Competitive pressures may dent the company's top line and growth prospects.

Last Earnings Report

Nektar Q1 Earnings & Revenues Top Estimates

Nektar Therapeutics reported an adjusted loss of 53 cents per share for the first quarter of 2020, narrower than the Zacks Consensus Estimate of a loss of 81 cents and the year-ago loss of 69 cents. Adjusted loss excludes a negative impact of 25 cents per share for impairment charges and additional costs related to the discontinuation of the NKTR-181 program.

Quarterly revenues were up 79.2% year over year to \$50.6 million owing to the recognition of a milestone payment during the quarter. Revenues also beat the Zacks Consensus Estimate of \$44.94 million.

Quarter Ending **03/2020**

Report Date	May 07, 2020
Sales Surprise	12.53%
EPS Surprise	34.57%
Quarterly EPS	-0.53
Annual EPS (TTM)	-2.36

Quarter in Detail

In the first quarter, product sales decreased 21.7% from the year-ago period to \$3.4 million. Non-cash royalty revenues were up 20.2% to \$9.9 million.

Nektar's royalty revenues decreased 14.7% year over year to \$9.7 million in the quarter.

License, collaboration and other revenues were \$27.5 million in the quarter compared with \$4.2 million in the year-ago quarter. The increase was due to the recognition of a \$25-million milestone payment from Bristol-Myers triggered by the initiation of the registrational study of Nektar's bempegaldesleukin plus Bristol-Myers' Opdivo in muscle-invasive bladder cancer.

Research and development expenses decreased 8% to \$109 million. Notably, the company had recorded pre-commercial manufacturing costs for NKTR-181 in the year-ago quarter, which was not present in the reported quarter and led to the decline in expenses. The company discontinued the development of NKTR-181 in January.

General and administrative expenses rose 4.8% to \$26.2 million in the reported quarter.

Pipeline Update

On the earnings call, the company stated that clinical studies in oncology conducted by the company have not experienced any significant delays. However, the company cautioned that uncertainties concerning COVID-19 may delay late-stage studies or enrollment of new patients in clinical studies in the future. Moreover, it expects a delay of approximately three months related to the previously anticipated timelines for certain earlier-stage studies, including the phase I/II PROPEL study evaluating bempegaldesleukin in combination with Merck's Keytruda in patients with select advanced or metastatic solid tumors.

Meanwhile, the company expects a delay of three to six months in the anticipated timeline of its partner-sponsored clinical studies.

Recent News

NKTR-181 Gets Adverse Advisory Committee Decision – Jan 14

Nektar announced that two FDA advisory committees did not give recommendation for approval to its chronic pain candidate, oxycodogol, formerly known as NKTR-181. The company met Anesthetic and Analgesic Drug Products Advisory Committee, and Drug Safety and Risk Management Advisory Committee to discuss the new drug application (“NDA”) for oxycodogol. The company has withdrawn the NDA for the candidate and decided to stop further development of the candidate following the unfavorable decision.

The company stated that discontinuation of NKTR-181 development will help the company to generate cost savings in the range of \$75-\$125 million in 2020. The savings will be led by reduction in estimated costs related to planned NKTR-181 commercialization and post-approval studies.

Nektar Expands Bempeg Collaboration With Bristol-Myers – Jan 10

Nektar announced a revision to its strategic collaboration agreement related to development of bempeg with Bristol-Myers. The companies have agreed to a new joint development plan, per which they plan to initiate new registrational studies to evaluate bempeg in combination with Bristol-Myers’ PD-1 inhibitor, Opdivo, as a treatment for adjuvant melanoma and muscle-invasive bladder cancer. Bristol-Myers will separately fund and conduct a phase I/II study, evaluating the combination regimen, under the new deal terms. It will be a dose optimization study, followed by an expansion study in patients with non-small cell lung cancer in the first-line setting.

Valuation

Nektar's shares are up 8.6% in the year-to-date period but down 30.8% over the trailing 12-month period. Stocks in the Zacks sub-industry and sector are down 5.2% and 1.2%, respectively, in the year-to-date period. Over the past year, stocks in the sub-industry and sector are down 5.8% and 0.3%, respectively.

The S&P 500 Index is down 3.8% in the year-to-date period but up 5.2% in the past year.

The stock is currently trading at 30.32X trailing 12-month sales per share, which compares to 2.2X for the Zacks sub-industry, 3.05X for the Zacks sector and 3.33X for the S&P 500 index.

Over the past five years, the stock has traded as high as 55.8X and as low as 4.28X, with a 5-year median of 12.37X. Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$25.00 price target reflects 32.34X trailing 12-month sales per share.

The table below shows summary valuation data for NKTR

Valuation Multiples - NKTR					
		Stock	Sub-Industry	Sector	S&P 500
P/S TTM	Current	30.32	2.2	3.05	3.33
	5-Year High	55.8	4.28	4.07	3.68
	5-Year Low	4.21	1.69	2.28	2.43
	5-Year Median	12.37	2.62	3.2	3.2
P/B TTM	Current	3.22	1.62	4.29	4.23
	5-Year High	1101.7	13.3	5.06	4.56
	5-Year Low	NA	1.02	2.93	2.83
	5-Year Median	4.66	2.49	4.27	3.67

As of 06/22/2020

Industry Analysis Zacks Industry Rank: Top 29% (73 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
Alkermes plc (ALKS)	Neutral	2
Biogen Inc. (BIIB)	Neutral	3
BristolMyers Squibb Company (BMY)	Neutral	2
Gilead Sciences, Inc. (GILD)	Neutral	2
MerckCo., Inc. (MRK)	Neutral	3
Novo Nordisk AS (NVO)	Neutral	3
Dr. Reddys Laboratories Ltd (RDY)	Neutral	2
Roche Holding AG (RHHBY)	Neutral	3

Industry Comparison Industry: Medical - Drugs				Industry Peers		
	NKTR	X Industry	S&P 500	BIIB	NVO	RDY
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	2
VGM Score	F	-	-	A	B	B
Market Cap	4.17 B	114.06 M	21.83 B	43.13 B	159.99 B	8.82 B
# of Analysts	6	3	14	29	4	2
Dividend Yield	0.00%	0.00%	1.93%	0.00%	1.65%	0.49%
Value Score	F	-	-	A	B	C
Cash/Price	0.33	0.25	0.07	0.09	0.01	0.04
EV/EBITDA	-7.80	-2.08	12.63	5.65	18.22	20.35
PEG Ratio	NA	1.06	2.90	0.57	2.44	NA
Price/Book (P/B)	3.22	3.30	3.01	3.44	19.91	4.29
Price/Cash Flow (P/CF)	NA	11.20	11.47	6.84	24.05	14.04
P/E (F1)	NA	15.59	21.30	7.97	25.26	29.01
Price/Sales (P/S)	30.46	6.47	2.29	2.99	8.49	3.62
Earnings Yield	-12.12%	-15.25%	4.42%	12.54%	3.96%	3.46%
Debt/Equity	0.11	0.01	0.77	0.39	0.05	0.01
Cash Flow (\$/share)	-2.43	-0.49	7.01	38.63	2.82	3.79
Growth Score	F	-	-	B	B	B
Hist. EPS Growth (3-5 yrs)	NA%	6.56%	10.84%	17.18%	7.38%	4.60%
Proj. EPS Growth (F1/F0)	-12.50%	13.97%	-10.80%	-1.26%	9.35%	-34.23%
Curr. Cash Flow Growth	-161.76%	2.52%	5.46%	9.02%	-0.50%	40.31%
Hist. Cash Flow Growth (3-5 yrs)	NA%	5.72%	8.55%	11.97%	7.63%	5.28%
Current Ratio	3.79	3.68	1.29	1.73	1.00	1.79
Debt/Capital	9.89%	6.02%	45.14%	27.95%	5.00%	0.82%
Net Margin	-335.50%	-132.39%	10.53%	40.76%	31.91%	11.15%
Return on Equity	-28.84%	-63.37%	16.06%	49.22%	73.87%	19.83%
Sales/Assets	0.07	0.29	0.55	0.54	1.02	0.77
Proj. Sales Growth (F1/F0)	28.36%	0.00%	-2.66%	-2.71%	6.12%	0.25%
Momentum Score	B	-	-	A	B	B
Daily Price Chg	2.72%	0.30%	0.09%	-2.48%	0.58%	0.11%
1 Week Price Chg	11.37%	2.19%	0.92%	-2.96%	4.55%	1.49%
4 Week Price Chg	1.74%	0.78%	5.61%	-13.21%	4.80%	3.56%
12 Week Price Chg	29.79%	25.22%	16.49%	-16.40%	12.90%	32.24%
52 Week Price Chg	-30.84%	-14.07%	-6.63%	12.03%	32.46%	47.56%
20 Day Average Volume	1,246,767	353,243	2,841,862	2,131,590	1,462,185	225,411
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.04%	0.00%	0.00%
(F1) EPS Est 4 week change	0.00%	0.00%	0.00%	0.04%	0.84%	0.00%
(F1) EPS Est 12 week change	3.70%	-0.88%	-13.25%	1.66%	-3.35%	-3.17%
(Q1) EPS Est Mthly Chg	0.00%	0.00%	0.00%	-0.11%	0.00%	NA

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	F
Growth Score	F
Momentum Score	B
VGM Score	F

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.